| 0.39 | 1.00% |
| SLXP NASDAQSalix Pharmaceuticals Ltd. | |
Market Cap 2.283B Book Value 6.472 EBITDA -12.0M PEG Ratio 29.94 EPS -1.178 P/B Ratio 6.04 Short Ratio 6.50 Index Membership S&P Sector Healthcare Full Time Employees 395 Profile Get Profile for: Drug Related Products Open 39.06 High 39.58 Low 38.98 Volume 183.6 K Target Price 50.60 Current EPS -1.178 This Year EPS 0.03 Next Year EPS 1.55 This Year PE 1303.33 Next Year PE 25.23 | Symbol | SLXP | | Name | Salix Pharmaceuticals Ltd. | | Type | Stock | | Country | United States | | Exchange | NASDAQ |
| | Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. |
Company Summary more  Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars?Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Top Stories| | 2010-08-31 |  | |
| | |
Earnings Postmortem for NBTY; NTY, PRGO, SLXP, HLF
Learning Markets - Aug 31, 2010
NBTY, Inc. (NTY) [Chart - Analysis - News] released its most recent earnings statement about a month ago on Wednesday, July 28th. NBTY, Inc. beat expectations with a profit of $1.03 per share---21 ...
2010-08-31 |  | |
| | | 2010-08-30 |  | |
| | | 2010-08-30 |  | |
|
| | A rally among airlines and a surprise jump in factory orders pushed US stocks higher in choppy trading on Tuesday. 2010-09-02 |  | |
|
Community Discussions | | | (0.12) | 5.04% |
| MTEX NASDAQMannatech Inc. | |
Market Cap 59.9M Book Value 1.697 EBITDA -1.8M EPS -0.516 P/B Ratio 1.40 Short Ratio 3.90 Index Membership S&P Sector Healthcare Full Time Employees 502 Profile Get Profile for: Drug Related Products Open 2.35 High 2.36 Low 2.26 Volume 8 K Current EPS -0.516 Dividend Date 29-Jun-09 | Symbol | MTEX | | Name | Mannatech Inc. | | Type | Stock | | Country | United States | | Exchange | NASDAQ |
| | Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. |
Company Summary more  Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. The company offers various nutritional supplements that aid in optimizing overall health and wellness, including health solutions for children, and additional nutrients for specific body systems; optimal weight and fitness products to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion; and products to enhance the skin?s own natural texture, softness, and elasticity, including damaged areas, as well as to deliver antioxidants to the skin. It sells its products through a network of independent ... Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. The company offers various nutritional supplements that aid in optimizing overall health and wellness, including health solutions for children, and additional nutrients for specific body systems; optimal weight and fitness products to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion; and products to enhance the skin?s own natural texture, softness, and elasticity, including damaged areas, as well as to deliver antioxidants to the skin. It sells its products through a network of independent associates and members in United States, Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, Germany, South Africa, Singapore, Austria, the Netherlands, Norway, and Sweden. The company was founded in 1993 and is headquartered in Coppell, Texas. Mannatech Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. The company offers various nutritional supplements that aid in optimizing overall health and wellness, including health solutions for children, and additional nutrients for specific body systems; optimal weight and fitness products to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion; and products to enhance the skin?s own natural texture, softness, and elasticity, including damaged areas, as well as to deliver antioxidants to the skin. It sells its products through a network of independent ... Top Stories| | 2010-09-01 |  | |
| | |
Options Trader Alert for Mannatech Inc. (MTEX)
Market Intellisearch - Aug 26, 2010
NEW YORK (Market Intellisearch) -- Mannatech Inc. options saw heavy call activity today. A total of 13 call and 0 put contracts were traded raising a three month record high call volume alert ...
2010-08-26 |  | |
| | |
MSLP.OB, MTEX, OME 3 Companies Raising Quality of LIfe
Penny Stock Live - Aug 25, 2010
MusclePharm Corporation (OTCBB:MSLP.OB) one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products ...
2010-08-25 |  | |
| | | 2010-08-20 |  | |
|
Community Discussions |